Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
187 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016', provides in depth analysis on Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - The report reviews Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) Overview 11 Therapeutics Development 12 Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Stage of Development 12 Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Therapy Area 13 Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Indication 14 Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Products Glance 17 Late Stage Products 17 Early Stage Products 18 Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Companies 19 Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Universities/Institutes 30 Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Therapeutics Assessment 32 Assessment by Monotherapy/Combination Products 32 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 39 Advenchen Laboratories, LLC 39 Amgen Inc. 40 ArQule, Inc. 41 Astellas Pharma Inc. 42 AstraZeneca Plc 43 Asubio Pharma Co., Ltd. 44 AVEO Pharmaceuticals, Inc. 45 Bayer AG 46 BioArctic AB 47 Boehringer Ingelheim GmbH 48 Bristol-Myers Squibb Company 49 CardioVascular BioTherapeutics, Inc. 50 Celon Pharma Sp. z o.o. 51 Debiopharm International SA 52 Eddingpharm 53 Eisai Co., Ltd. 54 Eli Lilly and Company 56 F. Hoffmann-La Roche Ltd. 57 Hutchison MediPharma Limited 58 Incyte Corporation 59 Johnson & Johnson 60 Les Laboratoires Servier SAS 61 Metacrine Inc 62 Novartis AG 63 OncoMax 64 Principia Biopharma Inc. 65 Teva Pharmaceutical Industries Ltd. 66 Vichem Chemie Research Ltd. 67 Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Drug Profiles 68 Aea-25 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Aea-4 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 ARQ-087 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 ASP-5878 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 AZD-4547 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 BAY-1163877 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 BMS-986036 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 brivanib alaninate - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 CEP-11981 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 CPL-043 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 CVBT-141B - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 CVBT-141C - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 CVBT-141D - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 CVBT-141H - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 Debio-1347 - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 Drugs to Agonize Fibroblast Growth Factor Receptor 1 for Type 2 Diabetes - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 E-7090 - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 EDP-317 - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 erdafitinib - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 FGF-1 Program - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 HMPL-012 - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 HMPL-453 - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 INCB-54828 - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 infigratinib - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 lenvatinib mesylate - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 lucitanib - Drug Profile 115 Product Description 115 Mechanism Of Action 115 R&D Progress 115 LY-2874455 - Drug Profile 118 Product Description 118 Mechanism Of Action 118 R&D Progress 118 Monoclonal Antibody to Antagonize FGFR1 for Cancer - Drug Profile 119 Product Description 119 Mechanism Of Action 119 R&D Progress 119 nintedanib - Drug Profile 120 Product Description 120 Mechanism Of Action 120 R&D Progress 120 OMRCA-01 - Drug Profile 131 Product Description 131 Mechanism Of Action 131 R&D Progress 131 pazopanib hydrochloride - Drug Profile 133 Product Description 133 Mechanism Of Action 133 R&D Progress 133 pazopanib hydrochloride + pembrolizumab - Drug Profile 141 Product Description 141 Mechanism Of Action 141 R&D Progress 141 PRN-1371 - Drug Profile 142 Product Description 142 Mechanism Of Action 142 R&D Progress 142 Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 143 Product Description 143 Mechanism Of Action 143 R&D Progress 143 Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 144 Product Description 144 Mechanism Of Action 144 R&D Progress 144 regorafenib - Drug Profile 145 Product Description 145 Mechanism Of Action 145 R&D Progress 145 RG-7992 - Drug Profile 156 Product Description 156 Mechanism Of Action 156 R&D Progress 156 S-49076 - Drug Profile 157 Product Description 157 Mechanism Of Action 157 R&D Progress 157 SC-0806 - Drug Profile 159 Product Description 159 Mechanism Of Action 159 R&D Progress 159 Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile 160 Product Description 160 Mechanism Of Action 160 R&D Progress 160 SUN-11602 - Drug Profile 161 Product Description 161 Mechanism Of Action 161 R&D Progress 161 Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Dormant Projects 162 Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Discontinued Products 167 Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Featured News & Press Releases 170 Nov 07, 2016: Bayer Submits Supplemental New Drug Application for Stivarga (regorafenib) for Advanced Liver Cancer 170 Nov 07, 2016: Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer 171 Oct 26, 2016: Eisais LENVIMA (lenvatinib) Nominated for Galien Foundations Best Pharmaceutical Product 172 Oct 24, 2016: Efficacy of Ofev (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST 173 Oct 12, 2016: Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016 174 Oct 09, 2016: ESMO 2016: Lenvatinib Shows Promising Activity in Patients with RET-Positive Adenocarcinoma of the Lung 175 Oct 09, 2016: People with an Advanced Form of Thyroid Cancer Now Able to Benefit From Lenvima (lenvatinib) in Scotland 176 Oct 09, 2016: Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 178 Oct 08, 2016: Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders 178 Sep 30, 2016: Eisai To Initiate Phase III Clinical Study Of Anticancer Agent Lenvatinib As Potential First-Line Therapy For Advanced Renal Cell Carcinoma 179 Sep 29, 2016: Eisai To Present Latest Data On Lenvatinib At ESMO Congress 2016 180 Sep 28, 2016: Bayer to Showcase Regorafenib at ESMO 2016 Congress 181 Sep 28, 2016: Bayer presents New Data on BAY 1163877 at ESMO 2016 Congress 183 Sep 21, 2016: Eisai to Present Updates on Lenvatinib in Two Types of Thyroid Cancer at 86th Annual Meeting of the American Thyroid Association 183 Sep 15, 2016: Eisai Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma 185 Appendix 186 Methodology 186 Coverage 186 Secondary Research 186 Primary Research 186 Expert Panel Validation 186 Contact Us 186 Disclaimer 187
List of Tables
Number of Products under Development for, H2 2016 12 Number of Products under Development by Therapy Area, H2 2016 13 Number of Products under Development by Indication, H2 2016 14 Comparative Analysis by Late Stage Development, H2 2016 17 Comparative Analysis by Early Stage Products, H2 2016 18 Number of Products under Development by Companies, H2 2016 19 Number of Products under Development by Companies, H2 2016 (Contd..1) 20 Products under Development by Companies, H2 2016 21 Products under Development by Companies, H2 2016 (Contd..1) 22 Products under Development by Companies, H2 2016 (Contd..2) 23 Products under Development by Companies, H2 2016 (Contd..3) 24 Products under Development by Companies, H2 2016 (Contd..4) 25 Products under Development by Companies, H2 2016 (Contd..5) 26 Products under Development by Companies, H2 2016 (Contd..6) 27 Products under Development by Companies, H2 2016 (Contd..7) 28 Products under Development by Companies, H2 2016 (Contd..8) 29 Number of Products under Investigation by Universities/Institutes, H2 2016 30 Products under Investigation by Universities/Institutes, H2 2016 31 Assessment by Monotherapy/Combination Products, H2 2016 32 Number of Products by Stage and Mechanism of Action, H2 2016 34 Number of Products by Stage and Route of Administration, H2 2016 36 Number of Products by Stage and Molecule Type, H2 2016 38 Pipeline by Advenchen Laboratories, LLC, H2 2016 39 Pipeline by Amgen Inc., H2 2016 40 Pipeline by ArQule, Inc., H2 2016 41 Pipeline by Astellas Pharma Inc., H2 2016 42 Pipeline by AstraZeneca Plc, H2 2016 43 Pipeline by Asubio Pharma Co., Ltd., H2 2016 44 Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 45 Pipeline by Bayer AG, H2 2016 46 Pipeline by BioArctic AB, H2 2016 47 Pipeline by Boehringer Ingelheim GmbH, H2 2016 48 Pipeline by Bristol-Myers Squibb Company, H2 2016 49 Pipeline by CardioVascular BioTherapeutics, Inc., H2 2016 50 Pipeline by Celon Pharma Sp. z o.o., H2 2016 51 Pipeline by Debiopharm International SA, H2 2016 52 Pipeline by Eddingpharm, H2 2016 53 Pipeline by Eisai Co., Ltd., H2 2016 54 Pipeline by Eli Lilly and Company, H2 2016 56 Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 57 Pipeline by Hutchison MediPharma Limited, H2 2016 58 Pipeline by Incyte Corporation, H2 2016 59 Pipeline by Johnson & Johnson, H2 2016 60 Pipeline by Les Laboratoires Servier SAS, H2 2016 61 Pipeline by Metacrine Inc, H2 2016 62 Pipeline by Novartis AG, H2 2016 63 Pipeline by OncoMax, H2 2016 64 Pipeline by Principia Biopharma Inc., H2 2016 65 Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 66 Pipeline by Vichem Chemie Research Ltd., H2 2016 67 Dormant Projects, H2 2016 162 Dormant Projects (Contd..1), H2 2016 163 Dormant Projects (Contd..2), H2 2016 164 Dormant Projects (Contd..3), H2 2016 165 Dormant Projects (Contd..4), H2 2016 166 Discontinued Products, H2 2016 167 Discontinued Products (Contd..1), H2 2016 168 Discontinued Products (Contd..2), H2 2016 169
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
